DD257426A5 - Verfahren zur herstellung von 1,5-benzothiazepin-derivaten - Google Patents
Verfahren zur herstellung von 1,5-benzothiazepin-derivaten Download PDFInfo
- Publication number
- DD257426A5 DD257426A5 DD87299117A DD29911787A DD257426A5 DD 257426 A5 DD257426 A5 DD 257426A5 DD 87299117 A DD87299117 A DD 87299117A DD 29911787 A DD29911787 A DD 29911787A DD 257426 A5 DD257426 A5 DD 257426A5
- Authority
- DD
- German Democratic Republic
- Prior art keywords
- cis
- methanol
- mixture
- benzothiazepine
- chloro
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 238000000034 method Methods 0.000 title claims abstract description 9
- KJFRSZASZNLCDF-UHFFFAOYSA-N 1,5-benzothiazepine Chemical class S1C=CC=NC2=CC=CC=C12 KJFRSZASZNLCDF-UHFFFAOYSA-N 0.000 title abstract description 3
- 150000003839 salts Chemical class 0.000 claims abstract description 10
- 150000001875 compounds Chemical class 0.000 claims description 29
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 13
- 125000000217 alkyl group Chemical group 0.000 abstract description 9
- 230000002490 cerebral effect Effects 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract description 3
- 239000001257 hydrogen Substances 0.000 abstract description 3
- 230000003276 anti-hypertensive effect Effects 0.000 abstract description 2
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 238000004220 aggregation Methods 0.000 abstract 1
- 230000002776 aggregation Effects 0.000 abstract 1
- 125000001589 carboacyl group Chemical group 0.000 abstract 1
- 229940124549 vasodilator Drugs 0.000 abstract 1
- 239000003071 vasodilator agent Substances 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 126
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 51
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 51
- 239000000203 mixture Substances 0.000 description 39
- -1 alkylammonium compound Chemical class 0.000 description 36
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 30
- 238000006243 chemical reaction Methods 0.000 description 30
- 239000000047 product Substances 0.000 description 30
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 24
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 24
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 24
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 21
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 239000002904 solvent Substances 0.000 description 14
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 12
- 238000005804 alkylation reaction Methods 0.000 description 11
- 230000029936 alkylation Effects 0.000 description 10
- 125000006239 protecting group Chemical group 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 239000002168 alkylating agent Substances 0.000 description 9
- 229940100198 alkylating agent Drugs 0.000 description 9
- 238000010992 reflux Methods 0.000 description 9
- 239000007858 starting material Substances 0.000 description 9
- 230000003287 optical effect Effects 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 239000012458 free base Substances 0.000 description 7
- 239000012442 inert solvent Substances 0.000 description 7
- 239000000741 silica gel Substances 0.000 description 7
- 229910002027 silica gel Inorganic materials 0.000 description 7
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 6
- 229910000027 potassium carbonate Inorganic materials 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
- 125000002252 acyl group Chemical group 0.000 description 5
- 150000001350 alkyl halides Chemical class 0.000 description 5
- 150000008051 alkyl sulfates Chemical class 0.000 description 5
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Substances CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 235000011121 sodium hydroxide Nutrition 0.000 description 4
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 3
- 150000008052 alkyl sulfonates Chemical class 0.000 description 3
- 229940085242 benzothiazepine derivative selective calcium channel blockers with direct cardiac effects Drugs 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 239000002026 chloroform extract Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 239000012024 dehydrating agents Substances 0.000 description 3
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 230000001077 hypotensive effect Effects 0.000 description 3
- 235000006408 oxalic acid Nutrition 0.000 description 3
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- VOJBMVZEUCIAIV-MSOLQXFVSA-N (2s,3s)-8-chloro-3-hydroxy-2-(4-methoxyphenyl)-5-[2-(methylamino)ethyl]-2,3-dihydro-1,5-benzothiazepin-4-one Chemical compound C1([C@@H]2SC3=CC(Cl)=CC=C3N(C([C@@H]2O)=O)CCNC)=CC=C(OC)C=C1 VOJBMVZEUCIAIV-MSOLQXFVSA-N 0.000 description 2
- UNCLRGCBQRNLAH-RTWAWAEBSA-N (2s,3s)-8-chloro-3-hydroxy-2-(4-phenylmethoxyphenyl)-3,5-dihydro-2h-1,5-benzothiazepin-4-one Chemical compound C1=CC([C@H]2[C@H](C(NC3=CC=C(Cl)C=C3S2)=O)O)=CC=C1OCC1=CC=CC=C1 UNCLRGCBQRNLAH-RTWAWAEBSA-N 0.000 description 2
- TYRZAGMAVZESQX-UHFFFAOYSA-N 2-amino-5-chlorobenzenethiol Chemical compound NC1=CC=C(Cl)C=C1S TYRZAGMAVZESQX-UHFFFAOYSA-N 0.000 description 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- YRFJCVDTZRWVMI-UHFFFAOYSA-N OC(=O)C(O)=O.S1N=CC(=O)CC2=CC=CC=C21 Chemical compound OC(=O)C(O)=O.S1N=CC(=O)CC2=CC=CC=C21 YRFJCVDTZRWVMI-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 125000005228 aryl sulfonate group Chemical group 0.000 description 2
- 150000007657 benzothiazepines Chemical class 0.000 description 2
- CKRLOOLWVKHPPE-RPBOFIJWSA-N benzyl n-[2-[(2s,3s)-8-chloro-3-hydroxy-2-(4-methoxyphenyl)-4-oxo-2,3-dihydro-1,5-benzothiazepin-5-yl]ethyl]-n-methylcarbamate Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](O)C(=O)N(CCN(C)C(=O)OCC=2C=CC=CC=2)C2=CC=C(Cl)C=C2S1 CKRLOOLWVKHPPE-RPBOFIJWSA-N 0.000 description 2
- GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000003218 coronary vasodilator agent Substances 0.000 description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 2
- 239000002024 ethyl acetate extract Substances 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 239000012264 purified product Substances 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- JHVKQEXNQYGGOH-AWEZNQCLSA-N (2s)-1-naphthalen-2-ylsulfonylpyrrolidine-2-carbonyl chloride Chemical compound ClC(=O)[C@@H]1CCCN1S(=O)(=O)C1=CC=C(C=CC=C2)C2=C1 JHVKQEXNQYGGOH-AWEZNQCLSA-N 0.000 description 1
- SLGQXZDAILNTQU-SJORKVTESA-N (2s,3s)-8-chloro-3-hydroxy-2-(4-hydroxyphenyl)-5-[2-(methylamino)ethyl]-2,3-dihydro-1,5-benzothiazepin-4-one Chemical compound C1([C@@H]2SC3=CC(Cl)=CC=C3N(C([C@@H]2O)=O)CCNC)=CC=C(O)C=C1 SLGQXZDAILNTQU-SJORKVTESA-N 0.000 description 1
- VDEXLXXWSBFGHU-MSOLQXFVSA-N (2s,3s)-8-chloro-5-[2-(dimethylamino)ethyl]-3-hydroxy-2-(4-hydroxyphenyl)-2,3-dihydro-1,5-benzothiazepin-4-one Chemical compound C1([C@@H]2SC3=CC(Cl)=CC=C3N(C([C@@H]2O)=O)CCN(C)C)=CC=C(O)C=C1 VDEXLXXWSBFGHU-MSOLQXFVSA-N 0.000 description 1
- DWOKUCFPFUCSID-MOPGFXCFSA-N (2s,3s)-8-chloro-5-[2-(dimethylamino)ethyl]-3-hydroxy-2-(4-methoxyphenyl)-2,3-dihydro-1,5-benzothiazepin-4-one Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](O)C(=O)N(CCN(C)C)C2=CC=C(Cl)C=C2S1 DWOKUCFPFUCSID-MOPGFXCFSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- FTUXVMVEKYLKGE-WECFPGDBSA-N (z)-but-2-enedioic acid;[(2s,3s)-8-chloro-5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3-dihydro-1,5-benzothiazepin-3-yl] acetate Chemical compound OC(=O)\C=C/C(O)=O.C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=C(Cl)C=C2S1 FTUXVMVEKYLKGE-WECFPGDBSA-N 0.000 description 1
- YGTUPRIZNBMOFV-UHFFFAOYSA-N 2-(4-hydroxybenzoyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(=O)C1=CC=C(O)C=C1 YGTUPRIZNBMOFV-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- 125000002774 3,4-dimethoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- UNCLRGCBQRNLAH-UHFFFAOYSA-N 8-chloro-3-hydroxy-2-(4-phenylmethoxyphenyl)-3,5-dihydro-2h-1,5-benzothiazepin-4-one Chemical compound S1C2=CC(Cl)=CC=C2NC(=O)C(O)C1C(C=C1)=CC=C1OCC1=CC=CC=C1 UNCLRGCBQRNLAH-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- OPWZGRJLTPKMRY-FDOHDBATSA-N C(C(=O)O)(=O)O.O(C)C1=CC=C(C=C1)[C@@H]1SC2=C(N(C([C@@H]1OC(C)=O)=O)CCNC)C=CC(=C2)Cl Chemical compound C(C(=O)O)(=O)O.O(C)C1=CC=C(C=C1)[C@@H]1SC2=C(N(C([C@@H]1OC(C)=O)=O)CCNC)C=CC(=C2)Cl OPWZGRJLTPKMRY-FDOHDBATSA-N 0.000 description 1
- 208000018152 Cerebral disease Diseases 0.000 description 1
- 206010011091 Coronary artery thrombosis Diseases 0.000 description 1
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- QLDJQTYPAYXCGD-RPWUZVMVSA-N OC1=CC=C(C=C1)[C@@H]1SC2=C(N(C([C@@H]1O)=O)CCN(C)CC1=CC=CC=C1)C=CC(=C2)Cl Chemical compound OC1=CC=C(C=C1)[C@@H]1SC2=C(N(C([C@@H]1O)=O)CCN(C)CC1=CC=CC=C1)C=CC(=C2)Cl QLDJQTYPAYXCGD-RPWUZVMVSA-N 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- QWYMPDUGHGXMNN-VMXYRSAXSA-N [(2S,3S)-5-[2-[benzyl(methyl)amino]ethyl]-8-chloro-4-oxo-2-(4-phenylmethoxyphenyl)-2,3-dihydro-1,5-benzothiazepin-3-yl] acetate oxalic acid Chemical compound C(C(=O)O)(=O)O.C(C1=CC=CC=C1)OC1=CC=C(C=C1)[C@@H]1SC2=C(N(C([C@@H]1OC(C)=O)=O)CCN(C)CC1=CC=CC=C1)C=CC(=C2)Cl QWYMPDUGHGXMNN-VMXYRSAXSA-N 0.000 description 1
- CGGKNKXBDNHFDR-SXOMAYOGSA-N [(2s,3s)-8-chloro-2-(4-methoxyphenyl)-5-[2-[methyl(phenylmethoxycarbonyl)amino]ethyl]-4-oxo-2,3-dihydro-1,5-benzothiazepin-3-yl] acetate Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C(=O)OCC=2C=CC=CC=2)C2=CC=C(Cl)C=C2S1 CGGKNKXBDNHFDR-SXOMAYOGSA-N 0.000 description 1
- KBZDZTFKFVPAGB-UHFFFAOYSA-N [hydroxy(dimethyl)-lambda4-selanyl]methane Chemical compound C[Se](C)(C)O KBZDZTFKFVPAGB-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 229910000272 alkali metal oxide Inorganic materials 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 125000003310 benzodiazepinyl group Chemical group N1N=C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000002528 coronary thrombosis Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- PSLIMVZEAPALCD-UHFFFAOYSA-N ethanol;ethoxyethane Chemical compound CCO.CCOCC PSLIMVZEAPALCD-UHFFFAOYSA-N 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- OTGHWLKHGCENJV-UHFFFAOYSA-N glycidic acid Chemical compound OC(=O)C1CO1 OTGHWLKHGCENJV-UHFFFAOYSA-N 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229940102396 methyl bromide Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- CRSMROBXMKUTAY-UHFFFAOYSA-N n,n-dimethylmethanamine;4-methylbenzenesulfonic acid Chemical compound C[NH+](C)C.CC1=CC=C(S([O-])(=O)=O)C=C1 CRSMROBXMKUTAY-UHFFFAOYSA-N 0.000 description 1
- PYIXYEMKFUOLDQ-UHFFFAOYSA-N n-benzyl-2-chloro-n-methylethanamine;hydrochloride Chemical compound [Cl-].ClCC[NH+](C)CC1=CC=CC=C1 PYIXYEMKFUOLDQ-UHFFFAOYSA-N 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000003444 phase transfer catalyst Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 125000005537 sulfoxonium group Chemical group 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 201000010875 transient cerebral ischemia Diseases 0.000 description 1
- HADKRTWCOYPCPH-UHFFFAOYSA-M trimethylphenylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)C1=CC=CC=C1 HADKRTWCOYPCPH-UHFFFAOYSA-M 0.000 description 1
- MDTPTXSNPBAUHX-UHFFFAOYSA-M trimethylsulfanium;hydroxide Chemical compound [OH-].C[S+](C)C MDTPTXSNPBAUHX-UHFFFAOYSA-M 0.000 description 1
- BPLKQGGAXWRFOE-UHFFFAOYSA-M trimethylsulfoxonium iodide Chemical compound [I-].C[S+](C)(C)=O BPLKQGGAXWRFOE-UHFFFAOYSA-M 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D281/02—Seven-membered rings
- C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61001845A JPS62161776A (ja) | 1986-01-07 | 1986-01-07 | １，５−ベンゾチアゼピン誘導体の製法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DD257426A5 true DD257426A5 (de) | 1988-06-15 |
Family
ID=11512884
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DD87299117A DD257426A5 (de) | 1986-01-07 | 1987-01-06 | Verfahren zur herstellung von 1,5-benzothiazepin-derivaten |
Country Status (14)
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5580867A (en) * | 1994-09-09 | 1996-12-03 | Universite De Montreal | Myocardial protection during ischemia and reperfusion |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57169476A (en) * | 1981-04-13 | 1982-10-19 | Hamari Yakuhin Kogyo Kk | Novel preparation of benzothiazepine derivative |
| JPS57175182A (en) * | 1981-04-22 | 1982-10-28 | Hamari Yakuhin Kogyo Kk | Novel preparation of benzothiazepin derivative |
| JPS58113186A (ja) * | 1981-12-28 | 1983-07-05 | Hamari Yakuhin Kogyo Kk | ベンゾチアゼピン誘導体の新規な製造法 |
| JPS58116476A (ja) * | 1981-12-29 | 1983-07-11 | Hamari Yakuhin Kogyo Kk | ベンゾチアゼピン誘導体の新規製造法 |
| US4567175A (en) * | 1983-06-03 | 1986-01-28 | Tanabe Seiyaku Co., Ltd. | 8-Chloro-1,5-benzothiazepine derivatives |
| US4585768A (en) * | 1984-04-10 | 1986-04-29 | Tanabe Seiyaku Co., Ltd. | 1,5-benzothiazepine derivatives and processes for preparing the same |
-
1986
- 1986-01-07 JP JP61001845A patent/JPS62161776A/ja active Granted
- 1986-12-15 IE IE326986A patent/IE59359B1/en not_active IP Right Cessation
- 1986-12-19 IL IL81039A patent/IL81039A/xx not_active IP Right Cessation
- 1986-12-29 PT PT84036A patent/PT84036B/pt not_active IP Right Cessation
- 1986-12-29 ES ES8603613A patent/ES2003642A6/es not_active Expired
- 1986-12-30 FI FI865343A patent/FI865343L/fi not_active Application Discontinuation
-
1987
- 1987-01-06 SU SU874028773A patent/SU1544187A3/ru active
- 1987-01-06 CA CA000526793A patent/CA1291134C/en not_active Expired - Lifetime
- 1987-01-06 DD DD87299117A patent/DD257426A5/de not_active IP Right Cessation
- 1987-01-06 KR KR1019870000022A patent/KR910002879B1/ko not_active Expired
- 1987-01-06 BG BG077954A patent/BG46747A3/xx unknown
- 1987-01-07 HU HU8752A patent/HU198031B/hu not_active IP Right Cessation
- 1987-01-07 CN CN87100139A patent/CN1030388C/zh not_active Expired - Fee Related
- 1987-01-07 AT AT0001687A patent/AT394367B/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| PT84036A (en) | 1987-01-01 |
| FI865343A0 (fi) | 1986-12-30 |
| IL81039A0 (en) | 1987-03-31 |
| CA1291134C (en) | 1991-10-22 |
| HUT45242A (en) | 1988-06-28 |
| JPS62161776A (ja) | 1987-07-17 |
| IE59359B1 (en) | 1994-02-09 |
| KR870007147A (ko) | 1987-08-17 |
| IL81039A (en) | 1991-07-18 |
| IE863269L (en) | 1987-07-07 |
| CN1030388C (zh) | 1995-11-29 |
| FI865343A7 (fi) | 1987-07-08 |
| ATA1687A (de) | 1991-09-15 |
| CN87100139A (zh) | 1987-08-12 |
| FI865343L (fi) | 1987-07-08 |
| BG46747A3 (bg) | 1990-02-15 |
| SU1544187A3 (ru) | 1990-02-15 |
| PT84036B (pt) | 1989-01-17 |
| JPH0573749B2 (enrdf_load_stackoverflow) | 1993-10-15 |
| AT394367B (de) | 1992-03-25 |
| KR910002879B1 (ko) | 1991-05-09 |
| ES2003642A6 (es) | 1988-11-01 |
| HU198031B (en) | 1989-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DD218619A5 (de) | Verfahren zur herstellung von neuen 8-chlor-1,5-benzothiazepin-derivaten | |
| EP0114270B1 (de) | Acylderivate von 1,4:3,6-Dianhydro-hexiten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel | |
| EP0234561A2 (en) | 2,3-Dihydro-2-phenyl-5-aminoalkyl-naphtho [1,2-b]-1,4-thiazepin-4(5H)-one derivatives | |
| EP0019688A1 (de) | Diazaverbindungen und Verfahren zu deren Herstellung | |
| DD239202A5 (de) | Verfahren zur herstellung von 9-chlor-1,5-benzothiazepin-derivaten | |
| DE68902001T2 (de) | Verfahren zur herstellung von s-metoprolol und dessen zwischenprodukten. | |
| DE69015682T2 (de) | Verfahren zur Herstellung von 1,5-Benzothiazepinderivaten. | |
| DE69030897T2 (de) | Verfahren zur Herstellung von 1,5-Benzothiazepin-Derivaten | |
| DE69105786T2 (de) | Harnstoffderivate, deren Herstellung sowie diese enthaltende pharmazeutische Zusammensetzungen. | |
| EP0622366A1 (de) | Kondensierte Chinolyl-dihydropyridine, Verfahren zu ihrer Herstellung und ihre Verwendung in Arzneimitteln zur Behandlung von Herz-Kreislauferkrangen | |
| DD257426A5 (de) | Verfahren zur herstellung von 1,5-benzothiazepin-derivaten | |
| AT401055B (de) | Verfahren zur trennung von derivaten der 3-(4-substituiertes-phenyl)glycidsäure | |
| DE69031187T2 (de) | Verfahren für die Racemattrennung von Zwischenprodukten, die bei der Herstellung von 1,5-Benzothiazepinen verwendbar sind | |
| DE4217103C2 (de) | Verfahren zur Herstellung eines Benzothiazepins durch Cyclisierung mit Phosphonsäuren | |
| DE3884518T2 (de) | Naphthothiazepin-Derivate und Verfahren zu ihrer Herstellung. | |
| KR20010021834A (ko) | 알킬옥시 퓨라논 유도체의 제조방법, 상기 방법으로 얻은화합물 및 상기 화합물의 용도 | |
| DE69018777T2 (de) | Benzothiazepine. | |
| DE69411387T2 (de) | Verfahren zur Herstellung von pharmazeutisch aktiven Benzothiazepinderivaten. | |
| DE2905637C3 (de) | 1,5-Benzothiazepin-Derivate | |
| US5183922A (en) | Process for the optical resolution of threo-2-hydroxy-3-(2'-aminophenylthio)-3-(4"-methoxyphenyl)-propionic acid | |
| DE4023773B4 (de) | Verfahren zur optischen Auftrennung von zur Herstellung von Diltiazem geeigneten Zwischenprodukten | |
| EP0320817A1 (de) | 2,3-Dihydro-2-phenyl-5-amino-alkyl-naphtho[2,1-b][1,4]thiazepinon-Derivate | |
| DE69601456T2 (de) | Verfahren zur Herstellung von optisch aktiven 3-Hydroxy-1,5-Benzothiazepinderivaten sowie Zwischenprodukte in diesem Verfahren | |
| US4640930A (en) | Naphtho(1,8-bc)-1,5-thiazocinones | |
| AT395010B (de) | Verfahren zur herstellung von 1,5-benzothiazepinderivaten und von deren salzen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ENJ | Ceased due to non-payment of renewal fee |